TY - CHAP M1 - Book, Section TI - Antithrombotic Therapy A1 - Leavitt, Andrew D. A1 - Price, Erika Leemann A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Antithrombotic TherapyFor patients with morbid obesity, standard doses of apixaban or rivaroxaban should be chosen rather than dabigatran or edoxaban.DOACs are not recommended for VTE treatment in the acute setting following bariatric surgery but can be considered for ongoing treatment after the initial 4 weeks of therapy.Heparins may be preferable as initial therapy in hospitalized patients with clinical instability and fluctuating renal or hepatic function, when bleeding risk is high, or when there is concern that thrombolysis may be required.Stevens SM et al. Chest. [PMID: 34352278] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193159051 ER -